Search results
Showing 31 to 45 of 59 results for chronic fatigue syndrome
This guideline sets out an antimicrobial prescribing strategy for acute cough associated with an upper respiratory tract infection or acute bronchitis in adults, young people and children. It aims to limit antibiotic use and reduce antibiotic resistance.
Remdesivir and tixagevimab plus cilgavimab for treating COVID-19 (TA971)
Evidence-based recommendations on remdesivir (Veklury) and tixagevimab plus cilgavimab (Evusheld) for treating COVID-19.
Summary of the evidence on rituximab for treating autoimmune haemolytic anaemia (AIHA) to inform local NHS planning and decision-making
Cardiac contractility modulation device implantation for heart failure (IPG655)
Evidence-based recommendations on cardiac contractility modulation device implantation for heart failure in adults. This involves placing a device under the skin of the chest, which delivers electrical pulses to make the heart contract more strongly.
View recommendations for IPG655Show all sections
Evidence-based recommendations on normothermic extracorporeal preservation of hearts for transplant after brainstem death. This technique is used to store a donor heart for longer before being transplanted.
Permanent His-bundle pacemaker implantation for treating heart failure (IPG694)
Evidence-based recommendations on permanent His-bundle pacemaker implantation for treating heart failure. This involves attaching a wire connected to a pacemaker to the heart’s electrical conduction pathway (through a vein).
View recommendations for IPG694Show all sections
Evidence-based recommendations on implantation of a left ventricular assist device for destination therapy in people ineligible for heart transplantation.
Tivozanib for treating advanced renal cell carcinoma (TA512)
Evidence-based recommendations on tivozanib (Fotivda) for treating advanced renal cell carcinoma in adults.
Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemia (TA552)
Evidence-based recommendations on liposomal cytarabine–daunorubicin (Vyxeos) for untreated acute myeloid leukaemia in adults.
Evidence-based recommendations on exagamglogene autotemcel (Casgevy) for treating severe sickle cell disease in people 12 years and over.
This guideline covers diagnosing and managing rheumatoid arthritis. It aims to improve quality of life by ensuring that people with rheumatoid arthritis have the right treatment to slow the progression of their condition and control their symptoms. People should also have rapid access to specialist care if their condition suddenly worsens.
C3 glomerulopathy in the native kidney: eculizumab (ESUOM49)
Summary of the evidence on eculizumab for treating C3 glomerulopathy in the native kidney inform local NHS planning and decision-making
Evidence-based recommendations on infliximab (Remicade, Inflectra or Remsima), adalimumab (Humira) and golimumab (Simponi) for treating moderate to severe ulcerative colitis in adults, and on infliximab for treating severe active ulcerative colitis in children and young people of 6–17 years.
Cerebral palsy in under 25s: assessment and management (NG62)
This guideline covers diagnosing, assessing and managing cerebral palsy in children and young people from birth up to their 25th birthday. It aims to make sure they get the care and treatment they need for the developmental and clinical comorbidities associated with cerebral palsy, so that they can be as active and independent as possible.
Evidence-based recommendations on leniolisib (Joenja) for treating activated phosphoinositide 3-kinase delta syndrome in people 12 years and over.